Holen Sie sich die Stockscreener-App
10.46
3.86%
-0.42
Handel nachbörslich:
10.44
-0.02
-0.19%
Schlusskurs vom Vortag:
$10.88
Offen:
$10.85
24-Stunden-Volumen:
855.06K
Relative Volume:
0.74
Marktkapitalisierung:
$566.77M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.7087
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
-5.85%
1M Leistung:
+1.85%
6M Leistung:
+6.09%
1J Leistung:
+570.51%
1-Tages-Spanne:
$10.36
$11.00
1-Wochen-Bereich:
$10.12
$11.75
52-Wochen-Spanne:
$1.47
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.46 | 566.77M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions (NYSE:EBS) Trading Down 7%Here's Why - MarketBeat
Emergent BioSolutions (NYSE:EBS) Shares Down 3.9%What's Next? - MarketBeat
Where are the Opportunities in (EBS) - Stock Traders Daily
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent BioSolutions’ CEO Sold $11 Million worth of stock before error in Baltimore went public - WBAL Radio
Emergent BioSolutions Inc. to Host Earnings Call - ACCESS Newswire
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Emergent BioSolutions Inc (EBS) Stock Price Up 3.4% on Jan 24 - GuruFocus.com
Emergent BioSolutions (NYSE:EBS) Trading 7.2% HigherTime to Buy? - MarketBeat
Emergent seeking to reverse fortunes and become a major overdose treatment player - Pharmaceutical Technology
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Emergent BioSolutions stock reaffirms buy rating on contract modification - MSN
Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Emergent BioSolutions stock reaffirms buy rating on contract modification By Investing.com - Investing.com UK
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts - Benzinga
EBS (Emergent BioSolutions) Revenue : $1,094 Mil (TTM As of Sep. 2024) - GuruFocus.com
Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News
Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
EBS (Emergent BioSolutions) Free Cash Flow : $138 Mil (TTM As of Sep. 2024) - GuruFocus.com
Emergent BioSolutions gains exclusive commercial rights to KLOXXADO - MSN
Africa CDC Launches Groundbreaking Pan-African Mpox Treatment Trial in DRC - StockTitan
Emergent BioSolutions presents at healthcare conference By Investing.com - Investing.com Australia
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference - TipRanks
Emergent BioSolutions presents at healthcare conference - Investing.com
Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock - MarketBeat
StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy - MarketBeat
Emergent secures rights to KLOXXADO nasal spray By Investing.com - Investing.com Canada
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - The Malaysian Reserve
Hikma announces exclusive commercial partnership with Emergent B - GuruFocus.com
Emergent secures rights to KLOXXADO nasal spray - Investing.com
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - The Manila Times
Emergent BioSolutions: Stock Is A Likely Winner In 2025 (NYSE:EBS) - Seeking Alpha
Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution - StockTitan
Emergent BioSolutions Expands Overdose Treatment Portfolio with Exclusive KLOXXADO Rights - StockTitan
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - The Manila Times
Emergent BioSolutions Secures $16.7M BARDA Contract for Ebola Treatment Development - StockTitan
Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - MSN
HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS) - MarketBeat
Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365% - Yahoo Finance
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military - Marketscreener.com
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - The Manila Times
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Marketscreener.com
Emergent BioSolutions Secures $20M Defense Contract for Anthrax Vaccine BioThrax - StockTitan
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):